Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001470831-26-000252 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-06 | 2026-03-04 | BBIO | Ellis Andrea | Dir | M - OptEx | $8.45 | +64.9K | 83.5K | +349% | +$548.6K |
| D | 2026-03-06 | 2026-03-04 | BBIO | Ellis Andrea | Dir | S - Sale+OE | $64.87 | -64.9K | 18.6K | -78% | -$4.21M |
| D | 2026-03-06 | 2026-03-04 | BBIO | Ellis Andrea | Dir | M - OptEx | $0.00 | -64.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-04 | M | A | 64,921 | $8.45 | 83,510 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-04 | S | D | 64,921 | $64.87 | 18,589 | D | — | — | (F2) Represents the weighted average sale price of the shares sold from $64.255 to $65.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (right to buy) | 2026-03-04 | M | D | 64,921 | $0.00 | 0 | D | $8.45 · — to 2032-06-22 | 64,921 Common Stock | (F3) The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |